Mesenchymal Stem Cell Exosomes for Retinal Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal degenerative diseases, such as macular degeneration and hereditary retinal diseases, lack effective methods to prevent or regenerate lost retinal cell degeneration due to genetic abnormalities, aging, inflammation, vascular disease, etc., ultimately leading to blindness.
Innovation Solution
A composition comprising exosomes extracted from human-derived mesenchymal stem cells, particularly tonsil-derived mesenchymal stem cells, is administered to prevent or treat retinal degenerative diseases, with a concentration of 1×10^10 to 5×10^11 particles/ml and a size of 100 to 150 nm, leveraging their anti-vascular, anti-inflammatory, anti-fibrotic, and neuroprotective properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct stem cell therapy is applied to treat retinal degenerative diseases, then treatment effectiveness may be improved, but safety risks increase due to transformation into fibroblasts causing blindness
Solution Approach 1:
The patent extracts exosomes from mesenchymal stem cells and uses only these extracellular vesicles for treatment, separating the therapeutic active components from the problematic whole stem cells that can transform into fibroblasts. This extraction approach maintains therapeutic effectiveness while eliminating the safety risks associated with direct stem cell injection.
Solution Approach 2:
Exosomes serve as an intermediary carrier that delivers therapeutic factors from mesenchymal stem cells to retinal cells without requiring the stem cells themselves to be present in the eye. This intermediary mechanism allows therapeutic action to occur while avoiding the harmful transformation risks of direct stem cell therapy.
2Reliability
If retinal cell regeneration therapy is developed, then treatment for retinal degeneration can be provided, but the complexity of achieving safe and effective regeneration increases
Solution Approach 1:
The patent uses exosomes as temporary, disposable carriers that deliver therapeutic factors without requiring long-term presence or integration of complex regenerative structures. The exosomes are administered, perform their therapeutic function, and are naturally cleared, simplifying the overall therapy design compared to permanent regenerative implants or cell therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The exosome composition effectively inhibits retinal cell apoptosis and promotes cell viability, as demonstrated by in vitro and in vivo tests, providing a safer and more effective treatment option than direct stem cell therapy.
Implementation Method 1
Exosomes included in the composition of the present invention are extracellular vesicles (EVs) that are mediators for delivering secretory factors of stem cells
Implementation Method 2
The composition of the present invention has an excellent effect in preventing or treating a retinal degenerative disease by inhibiting the toxicity of substances that cause apoptosis of retina cells
Data Source
AI summary
One aspect of the present disclosure is a composition for preventing or treating a retinal degenerative disease, capable of preventing or delaying retinal cell degeneration. The composition for preventing or treating a retinal degenerative disease, in one aspect, contains exosomes extracted from human-derived mesenchymal stem cells as an active ingredient.